Biotech Values

[tinkershaw]

Which may allow Teva to convince the Judge that NVS/MNTA’s patent-infringement lawsuit should be dismissed as moot, averting legal discovery that might be highly embarrassing to Teva.

Funny how Bill Marth had Teva's General Counsel at the presentation. I don't ever recall having General Counsel present at a presentation other than with Rambus, and Rambus's entire company is dependent upon its patent and antitrust suits. Maybe he was just there to advise on the copaxone suit, but Bill Marth never deferred to the General Counsel on legal questions.

Maybe reading too much into it, but this may be a very astute observation.

Tinker